SMO and chronic myelogenous leukemia, BCR-ABL1 positive: Chiarenza treated the CML cell lines K-562 and KU-812 with CUR61414 (Smo inhibitor), AT43 (Hh agonist), and MRTX, MRT94, 92, and 83 (Smo-specific inhibitory compounds derived from acylguanidine).